NVision is already using quantum physics in everyday clinical practice with its POLARIS platform. The technology amplifies MRI signals many times over and makes metabolic processes in the body visible much earlier than conventional imaging. As a result, researchers receive indications of the response to a therapy within a few days instead of weeks or months. Now comes the next step. During the development of POLARIS, the company discovered a new class of organic qubits. PIQC, its own quantum computing platform, is being created on this basis. The idea behind it is as simple as it is ambitious. In future, quantum computers will design new drug candidates, while quantum sensors will test their effectiveness directly in a biological environment. NVision is thus pursuing an integrated approach of calculation and validation that could bring the traditionally separate worlds of drug design and clinical research closer together. In addition to Abbott, the expansion is supported by investors such as Playground Global and the European Investment Bank. The technology is still in its infancy. But while many quantum companies are still waiting for the big breakthrough, NVision already has systems in clinical use. It is precisely this combination of scientific vision and practical applicability that could become a decisive competitive advantage for the healthcare sector.
News of "NVision Quantum Technologies GmbH" from 13 May 2026